Hypertension is the world's number one cause of death. It is the main cause for cardiovascular (CV) diseases. 1 In addition to that the complications and comorbidities associated with hypertensions include cerebrovascular disease, ischemic heart disease, cardiac and renal failure and stroke, as well as retino-and nephropathy. 2 In the last decades the prevalence of hypertension has increased and it is expected to do so further. 3 Overall the global prevalence of hypertension was reported as 26.4% based upon studies in adult populations, 4 13.5% of the global total deaths were caused by hypertension-related diseases. 5 By 2008 the prevalence was 30% and for about half of the hypertensive patients blood pressure (BP) was under control. 6 By 2025, the worldwide prevalence of hypertension is predicted to increase by 60% to a total of 1.56 billion. 7 Despite the availability of a wide range of antihypertensive medications, about 
45.5% oftreated patients in the US fail to achieve a BP control target of less than 140/90 mmHg. 3 In European countries the number of patients not reaching BP control target varies from 59.7% in England to 81.3% in Spain, demonstrating substantial unmet need in the effective treatment of arterial hypertension. 8 Compliance is significantly influenced by the number of pills a patient is prescribed to take. 9 This 'pill burden' is further intensified by the high rate of comorbidities that often need treatment. Therefore, single-pill combination regimens have been developed. In addition to increased adherence, combination therapies can have beneficial effects on hypertension control when drugs with different mechanisms are combined. 10 The combination of the calcium channel blocker amlodipine and the angiotensin II receptor blocker valsartan has shown to have an improved efficacy and safety profile compared with monotherapy. 11, 12 Hence, there is a strong rationale for exploration of real-life practices in hypertension treatment in this country and providing evidence for antihypertensive efficacy and tolerability for widely used medications by western populations in these regions. International hypertension guideline acknowledge that most patients will require two or more antihypertensive medications to achieve BP control, either as separate agents or in a single pill combination. One of the combinations recommended by the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guideline is the combination of a calcium channel blocker (CCB) and an angiotensin receptor blocker (ARB). As amlodipine is the most widely prescribed CCB and valsartan is one of the most prescribed ARBs, the present study was conducted to establish the clinical usefulness, including antihypertensive effectiveness, safety, and tolerability, of their free-dose combination in a real-life outpatient setting.
Methods:
This prospective, open-label, non-comparative observational, multicenter study was conducted from July 2013 to October 2014 in different hospitals in Bangladesh. The study population consisted with male and female outpatients, aged >18 years with established diagnosis of hypertension, for whom the treating physician recommended treatment with single pill combination (SPC) of amlodipine and valsartan in adherence with the prescribing information and who provided the consent. The observational period was 26 ± 8 weeks which covered at least 3 examinations for each patient according to the routine in daily practice. In case of discontinuation or interruption of treatment, the reason had to be given.The assignment of the patient to the therapy was decided within the current practice and the medical indication, and was clearly separated from the decision to include the patient in the study. Patient demographic and baseline characteristic data were taken at study entry include age, weight and height, treatment for hypertension received in the 12 months prior to study entry. Information about the physical examination, performed according to physicians' routine practice, were documented in the source documentation at the study site. Significant findings that are presented prior to study entry was recorded as medical conditions in the study CRF. Significant findings made after the start of the study which met the definition of an adverse event (AE) was recorded as AEs in the study CRF. Data on blood pressure, heart rate, weight measured at study entry (V1) and at approximately week 4 (V2) and week 26 ± 8 weeks (V4) intervals and height measured at entry (V1) were collected. The mean of three sitting blood pressure values were recorded. Body weight was measured with the patient in street clothes and without shoes to be rounded up (if >0.5 kg) or down (<0.5 kg) to the nearest kilogram. Height was recorded in centimeters.The arm in which the highest sitting diastolic pressures was found was the arm used for all subsequent readings throughout the study and was done by the same staff member at the same time of day, using the same equipment, at every visit. Using a calibrated standard sphygmomanometer and appropriate size cuff, arterial blood pressure determinations was made in accordance with the 1988 AHA Committee Report 12 on blood pressure determination with the arm supported at the level of the heart, systolic pressure were recorded when the initial sound was heard (Phase I of the Korotkoff sound); diastolic pressure was recorded at the disappearance of the sound (Phase V of the Korotkoff sound). The cuff was deflated at a rate not greater than 2mmHg/ sec. At each study visit, after having the patient in a sitting position for five minutes, systolic/diastolic blood pressure was measured three times. The repeat measurements were made at one-to-two minute intervals. The mean of all three sitting measurements was decisive for the study specific procedures. No up or down rounding was allowed. Effectiveness, tolerability and compliance were assessed by the investigator at the end of study using a subjective evaluation scale. All AEs-including serious adverse events (SAEs) and safety endpoints (where relevant) was collected and was recorded in the study database, irrespective of causal association. Eligible patients were included in the study after they provided informed consent, and if they were incapable of doing so, they were included after such consent was provided by a legally acceptable representative of the patient. The primary effectiveness variable was the status effect of amlodipine/valsartan as monotherapy on change from baseline blood pressure after 26 weeks treatment. A two-sided t-test was used to assess the change from baseline blood pressure. A p-value less than 0.05 indicated that the mean change from Baseline in the treatment group was significantly different from zero. The magnitude of this change from Baseline was assessed by the mean of the estimated difference. Supportive analyses for the change from Baseline blood pressure was carried out using an analysis of covariance (ANCOVA) model.
Results:
The study enrolled 278 patients. Of these 236(84.9%) patients completed the study while 42(15.1%) patients discontinued. The only reasons for discontinuation were lost to follow-up [42(15.1%)]. Non-serious adverse events were reported in 19(6.8%) cases though treatment had been continued and finally completed to those patients. The mean age of patients was 49.74 (±13.27) years, and majority 217(78.1%) were less than or equal to 60 years of age (Table I) . (Table V) .
Good tolerability was reported in majority of the patients which were 187(71.6%) cases followed by very good and average which were 58(22.2%) patients and 16(6.1%) patients respectively. Among the 278 patients no death was reported after taking the amlodipine/valsartan drug. Furthermore there was no severe adverse effect was reported. Oedema was the only reported non-serious adverse events which was 19(6.8%) cases. However the rash had not been reported in this study.
Discussion:
Hypertension is among the leading causes of death worldwide. 3 Efficacy and safety profile of single pill combination (SPC) of amlodipine/valsartan demonstrated in randomized controlled trials, although critical, is not entirely reflected in daily clinical practice. 4, 7 Limited patient numbers determined by stringent inclusion and exclusion criteria of RCT preclude application of its findings to a larger population. Observational studies are needed to examine the effectiveness of a drug previously documented to be efficacious how a drug works in daily practice, under ordinary and variable conditions, prescribed by licensed clinicians with varying degrees of knowledge and expertise, to treat a variety of eligible patients. An advantage of observational studies is the access to a large, diverse groups of patients who better represent the population to which a drug is prescribed, and safety and effectiveness data collected from these studies are more valuable for clinical practices. This study was described an observational, multicenter, prospective, open-label study to assess effectiveness, safety and tolerability in patients with arterial hypertension receiving amlodipine/ valsartan in a real-world setting. It is expected that this study will elucidate the "real-world" determinants of clinical response to amlodipine/ valsartan and enable building an evidence-based approach to treatment, medical education, and clinical support; ultimately leading to improved patient outcomes.In addition, the study has been monitored a large number of patients from diverse ethnic populations and has been allowed to evaluate subgroups with different ethnicity and different risk factors in terms of effectiveness, safety and tolerability.
Hypertension is an independent risk factor for cardiovascular diseases and each reduction of either 20 mmHg in systolic BP or 10 mmHg in diastolic BP correlates with a two fold decrease in the likelihood of a fatal coronary event. 13 To achieve the currently recommended BP goal of which is 140/90 mmHg and lower for spe-cific patient populations, it is estimated that at least 25% of patients will require combination therapy. 14, 15 The combined use of two different classes of antihyper-tensive drugs enables targeting of distinct biological pathways, thus enhancing efficacy compared with monotherapy. In addition, side effects caused by one drug class may be negated by the actions of another drug class that elicits opposing physiological compensatory mechanisms, resulting in a more favorable tolerability profile. [16] [17] [18] [19] Among the five main classes of antihypertensive drugs, the combination of either an angiotensin converting enzyme inhibitor (ACEi) or an ARB, which both inhibit the renin-angiotensin system, a calcium channel blocker is the most commonly used double-drug regimen. 20 Compared with separate tablets for each drug, fixed-dose combination (FDC) tablets are associ-ated with a higher rate of adherence to treatment, and, as a consequence, a greater proportion of patients attaining their BP goal over time. 21, 22 The management of hypertension is indeed a challenge especially in the elderly; high BP can occur in more than two thirds of individuals after the age of 65 years; and the elderly are known to be a population with low rates of BP control. 23 Clinical trials conducted exclusively in the elderly are limited, leading to disparity in the recommendations for optimal BP control offered by various committees or societies. 24 Major hypertension studies have shown that many patients with hypertension will require two or more antihypertensive drugs to achieve their BP goals, and addition of a further BP-lowering therapy particularly from another therapeutic class to an existing antihypertensive drug regimen is likely to deliver additional BP lowering and improved BP control. 24 It has been reported that amlodipine/ valsartan have provided incremental BP reductions in patients receiving prior monotherapy. 25 In addition, the reductions were consistent across different classes of prior antihypertensive monotherapy and dual combinations. The results observed were not dissimilar to those reported in previously conducted randomized clinical trials, such as the 16-week EX-FAST study where the amlodipine/valsartan combination delivered meaningful BP reductions in patients uncontrolled on antihypertensive monotherapy, including betablockers, CCB, ACEi, ARB and diuretics. 26 The present study findings of BP reductions with an amlodipine/valsartan in patients previously treated with monotherapy are also similar to those reported in another large observational study in a real-life setting and conducted in Chinese patients. 27 The results of the present study can be used in a generalized large and diverse group of patients suffering from hypertension to whom the drug is prescribed. The results of this study have demonstrated the effectiveness, safety and tolerability of amlodipine/valsartan in patients with hypertension in the general population in a real world settings.
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